Related Experiment Video

Updated: Feb 7, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K

New Drugs for Lowering LDL-Cholesterol

Codruţa Bădescu, Elena Rezuş, L Bădescu

    Revista Medico-Chirurgicala a Societatii De Medici Si Naturalisti Din Iasi
    |July 26, 2018
    PubMed

    Insights

    New therapies targeting PCSK9 offer hope for lowering LDL-Cholesterol when statins are insufficient. These treatments aim to reduce cardiovascular risk in high-risk patients and those with genetic lipid disorders.

    Area of Science:

    • Cardiovascular Medicine
    • Pharmacology
    • Biochemistry

    Background:

    • Low-density lipoprotein cholesterol (LDL-C) is a primary risk factor for cardiovascular disease.
    • While statins are the standard treatment, many patients require additional LDL-lowering therapies due to residual risk, hereditary conditions, or statin intolerance.
    • Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a crucial role in regulating LDL-Receptor activity.

    Purpose of the Study:

    • To review the therapeutic approaches targeting PCSK9 for hypercholesterolemia treatment.
    • To discuss the development and evaluation of novel LDL-lowering agents.
    • To highlight the ongoing investigation into the cardiovascular benefits of PCSK9 inhibition.

    Main Methods:

    • Review of scientific literature and clinical trial data concerning PCSK9 inhibitors.
    • Analysis of therapeutic strategies involving monoclonal antibodies and other molecules targeting PCSK9.
    • Examination of preclinical and clinical studies (Phase I-III) evaluating PCSK9-targeted therapies.

    Main Results:

    • Monoclonal antibodies targeting PCSK9 (alirocumab, evolucumab) received marketing approval in 2015.
    • Other PCSK9 inhibitors are in various stages of development, from preclinical to Phase III trials.
    • Significant research interest is focused on the cardiovascular benefits derived from PCSK9 inhibition.

    Conclusions:

    • PCSK9 inhibition represents a promising therapeutic avenue for managing hypercholesterolemia and reducing cardiovascular risk.
    • These novel therapies are essential for patients with high-risk profiles or those unresponsive to or intolerant of statins.
    • Further clinical evaluation is anticipated to confirm the cardiovascular benefits of these emerging treatments.

    More Related Videos

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

    Published on: November 17, 2018

    14.2K
    High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay08:18

    High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

    Published on: January 7, 2019

    9.6K

    Related Concept Videos

    Vapor Pressure Lowering03:28

    Vapor Pressure Lowering

    The equilibrium vapor pressure of a liquid is the pressure exerted by its gaseous phase when vaporization and condensation are occurring at equal rates:
    31.3K
    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    1.4K
    Cholesterol: Significance and Regulation01:29

    Cholesterol: Significance and Regulation

    Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
    Considering cholesterol and...
    1.4K
    Receptor-mediated Endocytosis01:39

    Receptor-mediated Endocytosis

    Overview
    111.1K
    Pharmacokinetics: Drug–Drug Interactions01:25

    Pharmacokinetics: Drug–Drug Interactions

    Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
    451
    Bioequivalence of Drugs: Drugs with Multiple Indications01:09

    Bioequivalence of Drugs: Drugs with Multiple Indications

    The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
    162